Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis

Journal of Immunology

Volumn 165, Issue 12, 2000, Pages 7064-7071

  Stager, S ^a   Smith, D F ^a   Kaye, P M ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HASPB 1 PROTEIN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIGEN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN LEISHMANIASIS; SPLEEN; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; VACCINATION; VISCERAL LEISHMANIASIS;

EID: 0034671822     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.12.7064     Document Type: Article

References (62)

1. Leishmaniasis
2. The epidemic of visceral leishmaniasis in Western Upper Nile, Southern Sudan course and impact from 1984 to 1994
3. Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis
4. Intracellular antimicrobial activity in the absence of interferon-γ effect of interleukin-12 in experimental visceral leishmaniasis in interferon-γ gene-disrupted mice
5. B7-2 blockade enhances T cell responses to Leishmania donovani
6. Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani
7. T-cell and cytokine responses in leishmaniasis
8. Phase 1 study of an inactivated vaccine against American tegumentary leishmaniasis in normal volunteers in Brazil
9. Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers
10. Vaccines against leishmaniasis
11. Progress on vaccines against parasites
12. Leishmania major production of recombinant gp63, its antigenicity and immnunogenicity in mice
13. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis
14. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis
15. Vaccine efficacy of Salmonella strains expressing glycoproteie 63 with different promoters
16. Vaccination with DNA encoding the imnmunodominant LACK parasite antigen confers protective immnunity to mice infected with Leishmania major
17. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection
18. IL-12 as an adjuvant for cell-mediated immunity
19. Expression cloning of a protective Leishmania antigen
20. Genetic vaccination against leishmaniasis
21. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis
22. + effector cells default to the Th2 pathway in interferon γ-deficient mice infected with Leishmania major
23. Expression of a hydrophilic surface protein in infective stages of Leishmania major
24. Characterization of a second protein encoded by the differentially regulated LmcDNA16 gene family of Leishmania major
25. Expression of hydrophilic surface proteins in infective stages of Leishmania donovani
26. Acylation-dependent protein export in Leishmania
27. Cloning, characterization and serological evaluation of K9 and K26 two related hydrophilic antigens of Leishmania chagasi
28. Serodiagnosis of Leishmania donovani infections assessment of enzymelinked immunosorbent assays using recombinant L donovani gene B protein (GBP) and a peptide sequence of L donovani GBP
29. Destruction of follicular dendritic cells during chronic visceral leishmaniasis
30. Host resistance-to the Khartoum strain of Leishmania donovani
31. Regulation of the expression of nitric oxide synthase and leishmanicidal activity by glycoconjugates of Leishmania lipophosphoglycan in murine macrophages
32. Vaccination against cutaneous leishmaniasis in a murine model II Immunologic properties of protective and nonprotective subfractions of soluble promastigote extract
33. Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection
34. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani
35. The role of IL-12 in regulation of T helper cell subsets in vivo lessons from experimental cutaneous leishmaniasis
36. The role of dendritic cells in the induction and regulation of immunity to microbial infection
37. In vivo microbial stimulation reduces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas
38. Paralysis of dendritic cell IL-12 production by microbial products prevents infection-induced immunopathology
39. A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-α production and expression of B7-1 in human monocyte-derived antigen-presenting cells
40. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12
41. LeIF a recombinant Leishmania protein that reduces an IL-12-mediated Th1 cytokine profile
42. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity T-T help via APC activation
43. Interleukin-12 production by dendritic cells the role of CD40-CD40L interactions in Th1 T-cell responses
44. Differential effects of LPS and CD40 ligand stimulations on the induction of IL-12 production by dendritic cells and macrophages
45. T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to reduce immunoglobulin class switching
46. Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells
47. Organ-specific immune responses associated with infectious disease
48. - T cell subsets to express IL-18 receptor and produce IFN-γ in response to IL-18
49. + T cell memory by short-term IL-4 exposure during T cell receptor stimulation
50. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection
51. Altered course of visceral leishmaniasis in mice expressing transgenic I-E molecules
52. + cells in experimental visceral leishmaniasis
53. Antimicrobial response of a T cell-deficient host to cytokine therapy effect of interferon-γ, in experimental visceral leishmaniasis in nude mice
54. + T cells in patients with melanoma
55. + T lymphocyte responses in vitro using dendritic cells
56. Induction of antitumor immunity using bone marrow-generated dendritic cells
57. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
58. Peptide-pulsed dendritic cells reduce antigen-specific CTL-mediated protective tumor immunity
59. Dendritic cell (DC)-based anti-infective strategies DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection
60. The dynamics of granuloma formation in experimental visceral leishmaniasis
61. Deficient expression of co-stimulatory molecules on Leishmania-infected macrophages
62. The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ-dependent